Australia Archives - AsiaPEVC.com

Agilex Biolabs’ Toxicology Tapped for SARS-CoV-2 Vaccine Research

Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.

TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.

The TetraQ toxicology team, whose recent COVID-19 vaccine work is featured in PubMed, is one of the most experienced in the region with more than 15 years of success with biotechs and university researchers. In addition, research costs can be offset by 43.5% with the attractive Australian Government clinical research incentive rebate for USA, Asia and European companies.

Agilex Biolabs works closely with Australia’s leading biotech R&D tax rebate specialist, Bentleys R&D Services, to ensure clients are aware of the R&D benefits.

Bentleys’ Managing Director Mike Burfield said the attractive 43.5% R&D rebate on clinical research spend can be applicable for the entire toxicology program.

“The rebate covers rodent toxicology services at TetraQ, while second species toxicology research conducted overseas can also be potentially eligible depending on the company, saving considerable costs in the pre-clinical stage.

Each year we have hundreds of biotech companies from around the world benefiting from this significant refund system operated by The Australian Government to attract clinical research.

However, it is vital that biotechs take advice prior to starting research, and that company documentation is prepared correctly from the start to take full advantage of these savings during the toxicology program, through to phase I and beyond.”

TetraQ toxicology, which was acquired by Agilex Biolabs earlier this year, started in 2005 based out of the University of Queensland and has since earned a strong global reputation for excellence in GLP rodent pre-clinical safety studies.

Agilex Biolabs CEO, Jason Valentine said:“Biotech clients are discovering the considerable speed and cost advantages of using an Australian-based toxicology facility like TetraQ.”The 43.5% rebate on toxicology costs is a major benefit, but clients are also keen to then leverage the easy and rapid transition to first-in-human trials available in Australia. Australia is known as the ideal early-phase destination because of the many regulatory and cost advantages – and most importantly that clinical data is accepted by the FDA and other major authorities.

TetraQ’s NATA-accredited, GLP-recognised rodent toxicology facility is highly regarded for its personalized service, rapid response, and innovative solutions for biotechs planning their first-in-human studies.”

TetraQ non-GLP toxicology study results can be used to support the design of both key efficacy studies and formal GLP toxicology studies in rodents. Formal GLP toxicity studies can in turn support first-in-human studies. GLP studies employ a test item manufactured under Good Manufacturing Practice (GMP) and a study design informed by non-GLP exploratory toxicity studies as well as the intended clinical use. GLP studies are subject to Quality Assurance (QA) audit, as their results are intended to facilitate the safe design of clinical studies.

The study management and data collection processes are supported by an FDA 21 CFR Part 11-compliant Provantis software system. Furthermore interim and final report preparation is also facilitated by this centralized data collection system to allow rapid delivery of written reports to clients.

Agilex Biolabs has more than 120 staff which includes 85 dedicated laboratory staff and supports client pharma and biotech companies from the US, Europe and APAC.

The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilizing the two platforms of LC-MS/MS and Immunoassay.

Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity.

Book a confidential briefing with our scientists before you start your next clinical trial.

About Agilex Biolabs

Agilex Biolabs, Australia’s leading bioanalytical and toxicology laboratory, has more than 24 years of experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. It has successfully supported hundreds of preclinical and clinical trials from around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition. The company has recently acquired TetraQ biolabs and toxicology, and also expanded its main labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the new lab video walkthrough here.

Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilizing LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flows cytometry (BD FACSymphony A3, 20 color cell analyzer).

Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

Immunophenotyping
Receptor occupancy
Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
PBMC assays and cellular mechanism of action assays

Agilex Biolabs Media Contact:
Kate Newton
Media@AgilexBiolabs.com

Avance Clinical Expands Gene Technology Clinical Trial Services to Meet $17.4 billion Market Demand

The leading Australian CRO for biotechs and Frost & Sullivan Asia-Pacific CRO Market Leadership Award winner, Avance Clinical, has expanded its gene technology clinical trial services to meet the increasing global demand predicted to reach $17.4 billion by 2023.

Avance Clinical is accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR).

This accreditation recognizes that Avance Clinical has the CRO resources and internal processes in place to effectively manage pre-clinical and clinical trials for products involving genetically modified organisms (GMOs).

In Australia, dealings with GMOs in clinical research require authorization under the Gene Technology Act 2000. The OGTR administers the Gene Technology Act 2000, and has specific responsibility to protect the health and safety of people, and to protect the environment, by identifying risks posed by or as a result of gene technology, and by managing those risks through regulating dealings with GMOs.

The global market for genetic modification therapies is expected to grow from $2.3 billion in 2018 to reach $17.4 billion by 2023, growing at a compound annual growth rate of 49.9% (BCC Research, 2018). The utilization of gene modification technologies used in COVID-19 vaccine products is likely to translate in further growth in this field of therapeutics.

Avance Clinical CEO Yvonne Lungershausen said OGTR accreditation is important for our international clients. “Our clients need to know that their CRO has all the necessary credentials and is capable of delivering the highest of clinical research standards in this exciting and rapidly evolving sector,” she said.

Avance Clinical currently has a number of GMO studies underway and is expanding its services further to accommodate increasing global demand.

Take the Quiz: Test your Knowledge about Australian Clinical Trials here. https://www.surveymonkey.com/r/Australian-Clinical-Trials

About Avance Clinical

Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.

Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field. Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.

Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Media Contact:
media@avancecro.com

Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today congratulated client Bionomics Limited (Bionomics) on its positive pharmacokinetic (PK) results from a 7-day dosing study in healthy volunteers using the newly developed solid dose oral tablet formulation of BNC210.

Liz Doolin, Bionomics’ Vice President Clinical Development commented that “We greatly value our long-standing partnership with Agilex Biolabs who continue to be a partner of choice for Bionomics and have supported the development of BNC210 from the beginning. We look forward to continuing this partnership into the future.”

Bionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5), is a global, clinical-stage biopharmaceutical company. Bionomics said in their announcement:

“BNC210 is a novel, negative allosteric modulator of the alpha 7 nicotinic acetylcholine receptor in development for the treatment of anxiety and stressor-related disorders, and in November 2019 was granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of Post-Traumatic Stress Disorder (PTSD).

The 7-day dosing PK study in ten healthy volunteers (females and males) demonstrated that at a dose of 900 mg given twice daily, the tablet formulation of BNC210 had steady-state 12-hourly exposure levels ranging from 33-57 mg.h/L which exceed the 12-hourly blood exposure of ~25 mg.h/L predicted as necessary to meet the primary endpoints for effectiveness for treating PTSD patients in future clinical trials.

Dr. Errol De Souza, Executive Chairman of Bionomics said, “We are extremely pleased with the results of the 7-day PK study which demonstrate that we reach steady-state levels on the second day following the start of twice-daily dosing and that we not only meet but exceed the blood exposure predicted from the pharmacometrics analysis as necessary for future trials.

“With the dose now selected, we can initiate manufacturing of the tablets, clinical site selection and regulatory filings in preparation for a Phase 2b trial with BNC210 in PTSD patients projected for mid-2021.”

Dr Kurt J. Sales Agilex Biolabs’ Director Immunoassay said: “Anxiety and stress-related disorders have a major impact on the health and wellbeing of hundreds of thousands of Australians with more than 1 in 4 people reported to be impacted by these disorders. The effects of stress and anxiety not only impact a person’s psychological well-being but also their physical well-being and productivity which in turn has a tremendous impact on the economy.

“Novel treatments such as BNC210 are essential weapons in the fight against anxiety and stress-related disorders. Agilex Biolabs has been working closely with Bionomics for several years, supporting the PK regulated Bioanalysis of BNC210 and is privileged to be a part of this potential new treatment for anxiety and stressor-related disorders.”

Agilex Biolabs’ world-class laboratories feature state-of-the-art equipment including Gyrolab Xplore, MSD Quickplex 120, Luminex Magpix, BD FACSymphony A3 flow cytometer and soon to be released, digital droplet quantitative real-time RT-PCR. The company offers services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilizing the two platforms of LC-MS/MS and Immunoassay.

Clients can also access a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program. Australian clinical trials have remained open for business and Agilex Biolabs is a designated essential service so clients can be assured of study continuity. Agilex Biolabs has more than 100 staff which includes 75 dedicated laboratory staff and supports client pharma and biotech companies from US, Europe and APAC.

Book a confidential briefing with our scientists before you start your next clinical trial.

About Agilex Biolabs

Agilex Biolabs, Australia’s leading bioanalytical laboratory, has more than 24 years’ experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world’s most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

Agilex Biolabs has the leading certifications including OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition. The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the new lab video walkthrough here: https://youtu.be/WNdPGkdr9FA

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilizing LC-MS/MS, immunoassay (Mesoscale, Gyrolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
– Immunophenotyping
– Receptor occupancy
– Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
– PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs media contact:
Kate Newton
Media@AgilexBiolabs.com

Tech leaders in Australia are gathering virtually to discuss the roadmap for the Future of AI in the Country

World AI Show is gearing up to virtually connect the most influential voices in Australia’s AI space this April. Notable speakers include the likes of Dr Kate Harrington, Head of Strategic Digital Initiatives, NSW Government Chief Information & Digital Office; Edward Santow, Human Rights Commissioner, Australian Human Rights Commission; Manohar Esarapu, CIO, City of Port Phillip & more.

Monday, 19 April 2021: Having hosted multiple high-level conferences across the world, World AI Show (WAIS) has established itself as the world?s biggest and elite AI show series. While it has proven itself as the quintessential AI event, World AI Show has a reputation of consistently getting global experts, investors, and cloud entrepreneurs – all under one roof.

Why Australia?

Intending to fund the development of the national AI Ethics Framework, technology roadmap, and set of standards, the Australian government has earmarked US$ 29.9 million in its 2018-19 budget for over four years to enhance the country?s efforts in artificial intelligence and machine learning.

The Victorian All-Party Parliamentary Group on Artificial Intelligence (VAPPGAI) was launched in Australia at the Parliament House on March 7, 2018. The AI parliamentary group aims to discuss the critical and transformative nature of AI from all sides of the political spectrum. AI and automation are already considered under the National Innovation Strategy and are also featured in several more recent initiatives.

“We generally talk about emerging technologies and how they impact society. But we have never seen a technology move as fast as AI and its impact on society and technology. In today’s world, the playing field is poised to become a lot more competitive. Businesses that don’t deploy AI and data to help them innovate will be at a huge disadvantage,” said Mithun Shetty, CEO of Trescon.

Taking place on 22 April 2021, World AI Show will feature keynotes from thought-leaders and industry experts, private networking sessions, private video meetings and more.

The show will be hosted on the virtual events platform Vmeets to help participants network and conduct business in an interactive and immersive virtual environment. Participants can also engage with speakers in Q&A sessions and network with solution providers in virtual exhibition booths, private consultation rooms and private networking rooms.

A ground-breaking collaboration of experts

Eager to keep the momentum from its previous editions, World Cloud Show will feature prominent experts such as Dan Jermyn, GM Chief Decision Scientist, Commonwealth Bank of Australia; Kshira Saagar, Chief Data Officer, Latitude Financial Services; Ruby Wolff, COO, Aramex; Ashwin Sinha, Chief Data Officer, Macquarie Bank; and Neal Cross – Co-Founder & Chairman, PictureWealth; to name a few.

#WorldAIShow – Australia will cover current topics including AI-driven digital transformation for enterprise, Accelerating and Operationalizing AI deployments within your organization, Enterprise analytics: Managing and making the most out of big data, Data visualization bringing business intelligence to life, AI & ML use cases across industries and more.

World AI Show – Australia is officially sponsored by Platinum Sponsor – Dataiku and Bronze Sponsor – Tiger Analytics.

About World AI Show

World AI Show is a thought-leadership-driven, business-focused, global series of events that takes place in strategic locations across the world. It connects top AI experts, enterprises, government representatives, data scientists, technology leaders, startups, investors, researchers, academicians, and global AI innovators – to discuss the impact of AI on commercial applications and the revolutionary ways it can transform businesses and government functions.

For more information visit: http://australia.worldaishow.com/

For further details about the announcement, please contact:
Karthik A
Marketing Lead
Trescon
marketing@tresconglobal.com

SunTec increases investments in Australia & New Zealand

Launches Xelerate Digital Core – A Low Risk, Progressive Digital Transformation Approach for Banks

SunTec Business Solutions, the leader in revenue management and customer experience orchestration solutions, announced the opening of its operations in Melbourne, Australia, increasing its focus on the Australia and New Zealand markets.

This is a significant move especially after SunTec’s recent launch of Xelerate(R) Digital Core – an extremely low risk approach for banks to accelerate their Digital transformation journey, without having to replace their functionally stable legacy core systems.

SunTec’s expansion comes at a time when many large banks in Australia and New Zealand are embracing customer centric transformation, to stay ahead of the competition. In addition, the recent regulatory requirements to improve standards and transparency, prevent misconduct and immediate remediation of customers makes it imperative for banks to act fast. But it is not an easy decision. On one hand banks are battling legacy issues while on the other, they are looking for technologies that can help them to quickly connect with the fintech ecosystem, create innovative products and own the customer experience. Xelerate(R) Digital Core ticks all boxes and simplifies the process by providing an intelligent and flexible middle layer that helps banks embrace a progressive digital transformation strategy.

Nanda Kumar, CEO of SunTec, said, “We are thankful to the growing acceptance we have received so far. Australia and New Zealand bear strategic significance in our growth plans. Setting up operations in Australia is a logical next step as it allows us to be close to our customers, strengthen our support and demonstrate our commitment to the region”.

SunTec is headquartered in India and has operations in USA, UK, Germany, Singapore and UAE. The Australia and New Zealand operations, which were being handled by the Singapore office will now be managed directly by the Melbourne office.

To find more on SunTec Xelerate, please visit: http://suntecgroup.com/

About SunTec(TM)

At SunTec, we help our clients increase the lifetime value of their customer relationships through effective revenue management and real-time customer experience orchestration. Our low risk digital transformation approach enables clients to own the customer experience by enhancing their value-based engagement. With 130+ clients in 45+ countries, SunTec is a trusted partner of leading organizations across Banking, Financial services, Insurance, Telecom and Travel industries. Headquartered in India, we have operations in USA, UK, Germany, UAE, Singapore and Australia.

For media enquiries, contact:
SunTec:
Anoop M George
Head-Corporate & Digital Marketing
Tel: +91-949 505 9292
Email: anoopmg@suntecgroup.com

Australia: Wesfarmers Selling Kmart Tyre and Auto Service to Continental

Australia-listed conglomerate Wesfarmers today announced it has agreed to sell its Kmart Tyre and Auto Service (KTAS) business to Continental AG for $350 million.

On successful completion of the transaction, Wesfarmers estimates it will report a pre-tax profit on sale of approximately $270 million to $275 million, subject to completion adjustments.

The sale is subject to certain consents and approvals including from the Australian Competition and Consumer Commission and the Foreign Investment Review Board.

KTAS is one of Australia’s largest tyre, automotive service, and repair retailers. The business has 258 stores in Australia with over 1,200 employees. It is also the largest single employer of apprentice motor mechanics in Australia.

Continental, based in Germany, will use the KTAS name and logo for a transitional period following the sale. Its five divisions in 2017 generated sales of €44 billion and it currently employs more than 243,000 people in 60 countries.

Continental’s Tire division is a technology leader in tyre production and offers a broad product range for passenger cars, commercial vehicles, and two-wheelers.

Its product portfolio also includes fleet applications, as well as digital management systems for commercial vehicle tyres.

Wesfarmers Managing Director Rob Scott said the agreement to sell KTAS crystallises value for shareholders from the business turnaround since it was acquired as part of the Coles Group in 2007.

“We believe that the divestment is in the best interests of Wesfarmers’ shareholders, while giving the employees and customers of KTAS the opportunity to join a highly complementary business in Continental. Continental’s automotive industry expertise will further strengthen the business’ customer offering,” Scott said.

Subject to satisfying conditions precedent, the divestment of KTAS is expected to complete in the first quarter of the 2019 financial year.

Last week, Wesfarmers also announced it has agreed to sell its 40 per cent interest in the Bengalla Joint Venture to its joint venture partner New Hope Corporation (ASX:NHC) for $860 million.

On successful completion of the transaction, Wesfarmers expects to report a pre-tax profit on sale of approximately $670 million to $680 million subject to completion adjustments.

Also Read: Keppel Capital To Launch A$1bn Wholesale Property Fund in Australia

Bengalla is currently owned 40 per cent by Wesfarmers, 40 per cent by New Hope, 10 per cent by Taipower and 10 per cent by Mitsui. The transaction is subject to regulatory approval and pre-emption rights under the Bengalla Joint Venture Deed. The sale of the interest in the Bengalla Joint Venture is expected to close in the fourth quarter of 2018. – AsiaPEVC.com

Keppel Capital To Launch A$1bn Wholesale Property Fund in Australia

Singapore’s Keppel Capital Ventures has partnered with Vicinity Centres (Vicinity), a retail property group listed on the Australian Securities Exchange, to establish a new private fund in Australia.

The proposed fund intends to invest in an initial A$1 billion ($740 million) portfolio of Australian retail properties currently owned by Vicinity. The MOU is subject to due diligence, definitive documentation and final board approvals of both parties.

Keppel Capital Ventures is a wholly-owned subsidiary of Keppel Capital Holdings, the asset management arm of Keppel Corporation Limited.

The parties intend to manage the proposed fund through a joint venture where Keppel Capital and Vicinity will each hold a 50 per cent stake.

“Vicinity is expected to initially inject approximately A$1 billion of retail assets located across five Australian states into the proposed fund, and continue to provide property and development services for these assets,” Keppel said in a disclosure to the Singapore Exchange Monday.

Each party is expected to initially hold up to a 10% equity interest in the proposed fund, which is targeted to close by the end of the first quarter in 2019.

The ongoing investment strategy of the proposed fund will be to own, acquire and grow a diversified portfolio of Australian retail assets with stable yields and potential long-term capital growth, underpinned by high occupancy rates, balanced lease expires and a diversified tenant base predominantly focused on non-discretionary spending.

“The proposed fund will benefit from Keppel Capital’s extensive investor network and Vicinity’s strong capabilities in the retail sector in Australia,” Keppel said.

As one of the largest retail property managers listed on the Australian Securities Exchange, Vicinity has a fully integrated asset management platform and A$26 billion in retail assets under management across 81 shopping centres.

“The proposed fund, which will be Keppel Capital’s first retail-focused real estate fund, will expand our track record in Australian real estate investments beyond office developments to include retail properties,” said Keppel capital CEO Christina Tan.

Also Read: Singapore: Keppel Offshore & Marine Secures $51m Contract

For Vicinity CEO and Managing Director Grant Kelly, global investors view the Australian retail property market favourably, with its transparency, stable and growing economy, and strong population growth particularly attractive.

“Keppel Capital is an ideal partner for Vicinity, with our aligned objectives of expanding our respective property funds platforms and delivering long-term sustainable growth for partners invested in those platforms,” he said.

Cushman & Wakefield Completes Acquisition of Australia’s Inc RE

Global real estate services firm Cushman & Wakefield has finalized its acquisition of Inc RE, an Australian capital markets firm specializing in commercial sales, acquisitions, and investment advisory.

With the acquisition, Inc RE will join Cushman & Wakefield’s Capital Markets Australian platform and be part of the company’s global Capital Markets network.

In a statement, Cushman & Wakefield said the acquisition bolsters its capital markets platform in the region and globally.

With the combination of our global Capital Markets professionals and the recent acquisition of Inc RE, Cushman & Wakefield is placed to deliver superior results for clients in key markets across the globe,” said Matthew Bouw, Chief Executive Officer, Asia Pacific at Cushman & Wakefield.

Cushman & Wakefield’s Australian Capital Markets practice will be led by Josh Cullen, Inc RE principal.

The team will comprise 14 brokers focused on institutional sales, international investments, acquisitions and investment advisory. Cullen will be supported by Rick Butler and leading brokers Steve Kearney and Mark Hansen.

“The acquisition complements our local Capital Markets platform and creates momentum for us in the Capital Markets landscape nationally. It provides us with opportunities to accelerate the growth of the company’s broader commercial real estate business, particularly in Asset Services and Agency Leasing,” James Patterson, Chief Executive, Australia and New Zealand said.

Also Read: Philippines: Pilmico Acquires Singapore’s Gold Coin for $334m

In addition to Josh Cullen, Rick Butler, Steve Kearney and Mark Hansen, Claire Zouroudis, Charles Long and Lisa Lee also will join the Cushman & Wakefield Capital Markets practice based in Sydney. Inc RE’s total transactions completed in the span of 18 months total $2.25 billion.

Cushman & Wakefield is among the largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. In 2017, the firm had revenue of $6.9 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services.